Join
Live feed
·
INSIDERFilingvia Quantisnow
CERo Therapeutics Holdings Inc. logo

Interim Chairman and CEO Ehrlich Christopher B converted options into 5,312,983 shares, increasing direct ownership by 1,110% to 5,791,808 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CERO· CERo Therapeutics Holdings Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CERO (CERo Therapeutics Holdings Inc.) and more on Quantisnow.